In contrast, an international multisite cohort study offered reassurance regarding the short-term efficacy of SGLT2 inhibitors, uncovering no elevated hazard of bladder cancer in comparison to glucagon-like peptide 1 receptor agonists (GLP1-RAs) or dipeptidyl peptidase IV inhibitors (DPP-4i) 45. The gene discussed is GLP1R; the disease is urinary bladder cancer.